Trial Profile
An Observational study evaluating Pirfenidone and Nintedanib treatment patterns, complaince and treatment discontinuations in patients with Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jul 2017
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- 13 Jul 2017 New trial record
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society